Suraksha Diagnostic Ltd vs Transgene Biotek Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Suraksha Diagnostic Ltd is ₹ 298.9 as of 23 Oct 15:30 . The P/E Ratio of Suraksha Diagnostic Ltd changed from 42.2 on March 2025 to 36.9 on March 2026 . This represents a CAGR of -6.49% over 2 yearsThe P/E Ratio of Transgene Biotek Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Suraksha Diagnostic Ltd changed from ₹ 1342 crore on March 2025 to ₹ 1187 crore on March 2026 . This represents a CAGR of -5.95% over 2 yearsThe Market Cap of Transgene Biotek Ltd changed from ₹ 34.7 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 years The revenue of Suraksha Diagnostic Ltd for the Jun '26 is ₹ 88.73 crore as compare to the Mar '26 revenue of ₹ 82.2 crore. This represent the growth of 7.94% The revenue of Transgene Biotek Ltd for the Jun '26 is ₹ 0.06 crore as compare to the Mar '26 revenue of ₹ 0.2 crore. This represent the decline of -70% The ebitda of Suraksha Diagnostic Ltd for the Jun '26 is ₹ 31.53 crore as compare to the Mar '26 ebitda of ₹ 25.15 crore. This represent the growth of 25.37% The ebitda of Transgene Biotek Ltd for the Jun '26 is ₹ -0.06 crore as compare to the Mar '26 ebitda of ₹ -0.13 crore. This represent the decline of -53.85% The net profit of Suraksha Diagnostic Ltd changed from ₹ 7.67 crore to ₹ 12.85 crore over 9 quarters. This represents a CAGR of 25.78% The net profit of Transgene Biotek Ltd changed from ₹ 0.2 crore to ₹ -0.39 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Suraksha Diagnostic Ltd changed from 0.76 % on March 2026 to 0.76 % on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Transgene Biotek Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Suraksha Diagnostic Ltd

Suraksha Diagnostic Limited was incorporated as Suraksha Diagnostic Private Limited' as a private limited company dated March 15, 2005, issued by the Deputy Registrar of Companies, West Bengal at Kolkata.
Subsequently, Company was converted into a public limited company and the name of Company was changed to Suraksha Diagnostic Limited', and a fresh certificate of incorporation dated July 16, 2024, was issued by the Registrar of Companies, Central Processing Centre. The Company is mainly engaged in running diagnostic centres for carrying out various pathological and radiological testing and medical consultation services in in East India.
In addition to integrated pathology and radiology testing services, it also offer omnichannel medical consultation services via online and offline modes to customers through 43 of its diagnostic centres which house 120 polyclinic chambers hosting 750+ doctors.

About Transgene Biotek Ltd

Founded in March 1990 by Dr. Koteswara Rao, Transgene Biotek Limited was one of the first Biotechnology companies in India.
Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc.
The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune. Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.

FAQs for the comparison of Suraksha Diagnostic Ltd and Transgene Biotek Ltd

Which company has a larger market capitalization, Suraksha Diagnostic Ltd or Transgene Biotek Ltd?

Market cap of Suraksha Diagnostic Ltd is 1,556 Cr while Market cap of Transgene Biotek Ltd is 19 Cr

What are the key factors driving the stock performance of Suraksha Diagnostic Ltd and Transgene Biotek Ltd?

The stock performance of Suraksha Diagnostic Ltd and Transgene Biotek Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suraksha Diagnostic Ltd and Transgene Biotek Ltd?

As of October 25, 2026, the Suraksha Diagnostic Ltd stock price is INR ₹298.9. On the other hand, Transgene Biotek Ltd stock price is INR ₹2.57.

How do dividend payouts of Suraksha Diagnostic Ltd and Transgene Biotek Ltd compare?

To compare the dividend payouts of Suraksha Diagnostic Ltd and Transgene Biotek Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.